Kyverna Therapeutics, Inc. 8-K

What Happened

• Kyverna Therapeutics (KYTX) filed a Form 8‑K (Regulation FD disclosure) after issuing two press releases: on April 20, 2026 it announced positive longer‑term follow‑up data from the Phase 2 portion of the KYSA‑6 Phase 2/3 registrational trial in generalized myasthenia gravis (gMG); on April 21, 2026 it announced positive primary analysis results from KYSA‑8, its registrational trial in stiff person syndrome (SPS). The therapy reported is mivocabtagene autoleucel (miv‑cel, KYV‑101). Kyverna held a conference call at 7:00 a.m. Eastern Time on April 22, 2026 to review the results.

Key Details

• Drug: mivocabtagene autoleucel (miv‑cel, KYV‑101).
• Trials: KYSA‑6 (Phase 2 portion of a Phase 2/3 registrational trial for gMG) and KYSA‑8 (registrational trial for SPS).
• Dates: press releases issued April 20 and April 21, 2026; conference call April 22, 2026 at 7:00 a.m. ET.
• Materials: presentation slides used for the conference call were furnished as Exhibit 99.1 to the Form 8‑K.

Why It Matters

• These announcements report positive data from registrational‑intended trials of Kyverna’s lead cell therapy candidate. Positive results in registrational trials are material milestones that could affect development timelines, regulatory strategy, and investor sentiment. The company provided a conference call and slides so investors can review efficacy and safety details; investors should review those materials for specific outcome measures and any disclosed safety information.